AstraZeneca withdraws Imfinzi indication in advanced bladder cancer

AstraZeneca said it has voluntarily withdrawn the U.S. FDA’s accelerated approval for immunotherapy Imfinzi (ingredient: durvalumab) after failing to prove its efficacy in the phase-3 study.The withdr [전체본문 2021-02-23 13:49:00Z]

관련뉴스

  1. Immunotherapy Pioneers Unveil Updated Efficacy Data of Single Infusion of Tisagenlecleucel CAR T-cell Therapy Immunotherapy Pioneers at Children’s Hospital of Philadelphia Unveil Updated Efficacy Data of Single Infusion of Tisagenlecleucel, plus First-of-Its-Kind Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy Newswise … (본문 전체 12/5/2018 3:12 AM)...

  2. Lion TCR T-cell therapy for liver cancer to undergo phase 1/2 trial Lion TCR received approval from the Health Sciences Authority in Singapore to perform a phase 1/2 multicenter clinical study of its LioCyx candidate for treating liver cancer relapse after liver transplant, according to a press release. “We are very … (본문 전체 8/21/2018 4:36 AM)...

  3. ‘Switchable’ CAR T-cell Therapy Kills Advanced Pancreatic Cancer Cells in Mice, Study Reports A “switchable” CAR T-cell immunotherapy was able to completely eliminate cancer in mice whose tumors came from cells of people with advanced pancreatic cancer, including cancer cells that had moved to distant organs, a new study reports. These … (본문 전체 9/12/2018 9:29 PM)...

  4. FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed. The first-in-human Phase 1 trial, called Allo-SHRINK … (본문 전체 8/2/2018 12:59 AM)...

  5. Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs of Efficacy in Advanced Colorectal Cancer CYAD-01 — Celyad‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to findings from two clinical trials. These … (본문 전체 11/20/2018 10:08 PM)...

  6. BioCardia brings on clinical affairs VP to move regenerative heart therapy through phase 3 BioCardia has brought on Mark Schwartz to be its vice president of clinical affairs, as it moves forward with a phase 3 trial of its cell therapy treatment for heart failure following a heart attack. Schwartz has helped lead clinical study design and … (본문 전체 11/8/2018 1:33 AM)...

  7. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb | Cancer Gene Therapy Chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown remarkable efficacy in treating tumors of lymphopoietic origin. Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive peripheral T-cell lymphomas (PTCL) has been demonstrated. [전체본문 2021-01-30 05:47:47Z]...

  8. Bavencio-Inlyta Combo Therapy Delays Disease Progression or Death in Advanced Renal Cell Carcinoma Study A combination of Bavencio (avelumab) and Inlyta (axitinib) significantly extends the time to disease progression or death in patients with untreated, advanced renal cell carcinoma (RCC), according to top-line results of a Phase 3 trial announced by Merck … (본문 전체 9/19/2018 10:24 PM)...

  9. Histogenics to seek FDA approval for cell therapy despite failed study Waltham biotech Histogenics Corp. said it still plans to seek FDA approval for its lead drug, a cell-based therapy for cartilage loss and other orthopedic knee damage, despite the failure of a late-stage trial on Wednesday. Histogenics (Nasdaq: HSGX) had … (본문 전체 9/6/2018 12:56 AM)...

  10. A cancer therapy developed at a CIRM Alpha Stem Cell Clinic tests its legs against breast cancer A Phase 1 clinical trial co-sponsored by CIRM and Oncternal Therapeutics, has started treating patients at UC San Diego (UCSD). The goal of the trial is to test the safety and anti-tumor activity of the Oncternal-developed drug, cirmtuzumab, in treating … (본문 전체 9/18/2018 1:35 AM)...

  11. Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) Novartis International AG /Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) . Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible for the content of this announcement. (본문 전체 8/27/2018 11:12 PM)...

  12. Novartis International AG: Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel) Novartis International AG / Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel) . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. (본문 전체 8/27/2018 2:23 PM)...

  13. Cancer Stem Cell Therapy Market Analysis 2018-2025 by Key Players: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems A closer look at the overall Cancer Stem Cell Therapy business scenario presented through self-explanatory charts, tables, and graphics images add greater value to the study. This press release was orginally distributed by SBWire New York, NY — (SBWIRE … (본문 전체 11/14/2018 4:17 PM)...

  14. Atara Bio’s cell therapy ATA190 shows encouraging action in early-stage MS study Results from a Phase 1 clinical trial evaluating Atara Biotherapeutics’ (ATRA-3.7%) ATA190, an off-the-shelf allogeneic T-cell immunotherapy, in patients with progressive multiple sclerosis (MS … (본문 전체 11/20/2018 4:40 AM)...

  15. Cell therapy for knee cartilage damage did not meet primary endpoint in phase 3 trial Histogenics Corporation announced in a press release that the phase 3 clinical trial of its restorative cell therapy NeoCart did not meet its primary endpoint of statistically significant improvement in pain and function 1 year after treatment compared … (본문 전체 9/27/2018 4:12 AM)...

  16. Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD MELBOURNE, Australia, Aug. 30, 2018 (GLOBE NEWSWIRE) — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that CYP-001, its lead Cymerus™ mesenchymal stem cell (MSC) product candidate … (본문 전체 9/1/2018 10:32 AM)...

  17. BRIEF-Novartis Receives Health Canada Approval Of Its Car-T Cell Therapy, Kymriah I * NOVARTIS – HEALTH CANADA HAS APPROVED KYMRIAH FIRST CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY TO RECEIVE REGULATORY APPROVAL IN CANADA Source text for Eikon: Further company coverage: ([email protected]) Our Standards:The Thomson … (본문 전체 9/6/2018 10:33 PM)...

  18. Best Managed WordPress Hosting Providers Study Released by WebHostingCat.com July 19, 2018 – Los Angeles, CA – WebHostingCat.com has just released their most comprehensive comparison study on the Best Managed WordPress Hosting Providers for 2018. Eight top managed WordPress hosts were evaluated and compared based on factors such … Date : 2018-07-20T01:57:00.000Z Source : http://itbusinessnet.com/article/Best-Managed-WordPress-Hosting-Providers-Study-Released-by-WebHostingCatcom-5497133...

  19. Study Of Obesity Among Africans. Part 1 of 2 Study Of Obesity Among Africans. A genetic transfiguring associated with an increased risk of heart disease, type 2 diabetes and other health problems is normal in Africans and people of African descent worldwide, according to a new study Dec 2013. (Source 11/11/2018 1:46 PM)...

  20. SCM-Genexine’s US venture CoImmune completes $45 mn financing CoImmune has successfully completed a series A financing worth $45 million to fund its immunotherapy pipeline, its Korean co-parents SCM Lifescience and Genexine said on Wednesday.The US biotech firm [전체본문 2020-11-04 15:31:00Z]...